Integra Lifesciences Holdings Corp. (IART)
NASDAQ:IART
Top Page
Integra Lifesciences
(NASDAQ:IART)
Select Model
Select Model
Rating:47Neutral
Price Target:
$9.50
▲(1.28% Upside)
Action:ReiteratedDate:02/27/26
The score is held down primarily by the sharp 2025 profitability/revenue deterioration and weakened cash generation, with technicals also leaning weak (below key long-term moving averages). The earnings call provides partial offset via guidance for improved cash flow, modest growth, and deleveraging, but tariff/remediation and organic growth pressure keep risk elevated.
Positive Factors
Balance-sheet Deleveraging
Material debt reduction in 2025 meaningfully lowers default and covenant risk and increases financial flexibility. A stronger balance sheet supports capital allocation for remediation, R&D and staged product relaunches, making recovery plans more credible over the next several quarters.
Negative Factors
2025 Profitability Collapse
A near-halving of revenue and a swing to very large losses materially erode operating leverage and raise execution risk. Restoring prior margins and returns will require sustained revenue recovery, margin repair and cash generation, which may take multiple quarters and stress operations.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance-sheet Deleveraging
Material debt reduction in 2025 meaningfully lowers default and covenant risk and increases financial flexibility. A stronger balance sheet supports capital allocation for remediation, R&D and staged product relaunches, making recovery plans more credible over the next several quarters.
Read all positive factors
Integra Lifesciences (IART) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$717.02M
Dividend YieldN/A
Average Volume (3M)682.69K
Price to Earnings (P/E)―
Beta (1Y)1.70
Revenue Growth4.99%
EPS Growth-7151.40%
CountryUS
Employees4,396
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)0.83
Shares Outstanding77,937,210
10 Day Avg. Volume691,147
30 Day Avg. Volume682,692
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.91
Price to Sales (P/S)0.58
P/FCF Ratio-30.70
Enterprise Value/Market Cap3.51
Enterprise Value/Revenue1.54
Enterprise Value/Gross Profit2.98
Enterprise Value/Ebitda-7.71
Forecast
1Y Price Target
$11.25Price Target Upside19.94% Upside
Rating ConsensusModerate Sell
Number of Analyst Covering5
EPS Forecast (FY)2.35
Revenue Forecast (FY)$1.67B
Integra Lifesciences Business Overview & Revenue Model
Company Description
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, and general surgery. It operates in two segments, Codman Specialty Surgical ...
How the Company Makes Money
Integra LifeSciences primarily makes money by selling medical devices, implants, and surgical-related products used in operating rooms and specialty procedures, generating revenue when healthcare providers purchase its products for patient care. I...
Integra Lifesciences Earnings Call Summary
Earnings Call Date:Feb 26, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:Apr 29, 2026
Earnings Call Sentiment Neutral
The call presented a balanced mix of operational progress and commercial momentum (product relaunches, new launches, leadership additions, supply improvements and modest revenue guidance), alongside material near-term financial and operational challenges (organic revenue declines, margin compression from remediation and tariffs, negative cash conversion in Q4 and elevated leverage). Management emphasized remediation, supply recovery and disciplined capital allocation with a clear plan to delever and improve free cash flow in 2026, but several uncertainties (tariff treatment, MediHoney timing and staged product ramp) keep the near-term outlook cautious.Positive Updates
Fourth Quarter Revenue and EPS Beat
Q4 2025 revenue of $435.0M and adjusted EPS of $0.83, both above the midpoint of guidance; sequential revenue improvement of $33M versus Q3 indicating improving supply and seasonality.
Negative Updates
Organic Revenue Pressure and Product Remediation
Full year 2025 organic revenue declined 0.7%; Q4 2025 organic decline of 2.5%. Tissue Technologies hit by remediation (MediHoney) and tough comps for Integra Skin, with Tissue Tech revenue down 12.8% year-over-year in Q4.
Read all updates
Q4-2025 Updates
Positive
Negative
Fourth Quarter Revenue and EPS Beat
Q4 2025 revenue of $435.0M and adjusted EPS of $0.83, both above the midpoint of guidance; sequential revenue improvement of $33M versus Q3 indicating improving supply and seasonality.
Read all positive updates
Company Guidance
Integra guided Q1 2026 revenue of $375–$390M (reported growth -2.0% to +1.9%; organic -3.4% to +0.5%), which includes an approximate 140 bps FX tailwind and a roughly $10M headwind from MediHoney and order timing, and Q1 adjusted EPS of $0.37–$0.45 (includes ~ $0.07 tariff impact). Full‑year 2026 revenue is guided to $1.66–$1.70B (reported growth 1.6%–4.1%; organic 0.8%–3.3%; ~80 bps FX tailwind) with adjusted EPS $2.30–$2.40 (about $0.32 tariff impact), gross margin roughly flat YoY, EBITDA margin improving ~40 bps, operating cash flow expected north of $200M (~$150M improvement vs. 2025), and deleveraging toward the top of a 2.5x–3.5x target by year‑end; guidance does not assume recovery of prior tariffs nor the new Section 122 tariff details.Integra Lifesciences Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
55
Neutral
Cash Flow
40
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.64B | 1.61B | 1.54B | 1.56B | 1.54B |
| Gross Profit | 845.23M | 882.06M | 884.74M | 970.31M | 944.64M |
| EBITDA | -326.20M | 193.29M | 255.96M | 384.60M | 366.33M |
| Net Income | -516.47M | -6.94M | 67.74M | 180.55M | 169.07M |
Balance Sheet | |||||
| Total Assets | 3.60B | 4.04B | 3.78B | 3.89B | 3.78B |
| Cash, Cash Equivalents and Short-Term Investments | 263.74M | 273.57M | 309.10M | 456.66M | 513.45M |
| Total Debt | 2.03B | 1.98B | 1.68B | 1.63B | 1.67B |
| Total Liabilities | 2.56B | 2.49B | 2.19B | 2.09B | 2.10B |
| Stockholders Equity | 1.04B | 1.55B | 1.59B | 1.80B | 1.68B |
Cash Flow | |||||
| Free Cash Flow | -31.05M | 24.96M | 73.09M | 217.38M | 264.35M |
| Operating Cash Flow | 50.38M | 129.38M | 139.96M | 264.47M | 312.43M |
| Investing Cash Flow | -108.06M | -390.81M | -94.18M | -58.58M | -161.44M |
| Financing Cash Flow | 28.34M | 237.86M | -229.93M | -251.95M | -98.23M |
Integra Lifesciences Technical Analysis
Negative
9.38
Price Trends
10.76
Negative
11.68
Negative
12.71
Negative
Market Momentum
-0.48
Negative
38.81
Neutral
72.40
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IART, the sentiment is Negative. The current price of 9.38 is below the 20-day moving average (MA) of 9.61, below the 50-day MA of 10.76, and below the 200-day MA of 12.71, indicating a bearish trend. The MACD of -0.48 indicates Negative momentum. The RSI at 38.81 is Neutral, neither overbought nor oversold. The STOCH value of 72.40 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IART.
Integra Lifesciences Risk Analysis
Integra Lifesciences disclosed 31 risk factors in its most recent earnings report. Integra Lifesciences reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Integra Lifesciences Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | $1.46B | 25.04 | 17.36% | ― | 29.47% | 23.24% | |
65 Neutral | $743.40M | 21.81 | 4.97% | ― | 1.58% | ― | |
56 Neutral | $1.07B | 26.78 | 4.68% | 2.02% | 4.69% | -51.57% | |
56 Neutral | $1.62B | -95.98 | -13.44% | ― | 18.72% | 85.77% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $461.66M | -6.56 | -20.38% | ― | 4.31% | 3.26% | |
47 Neutral | $717.02M | -1.85 | -39.90% | ― | 4.99% | -7151.40% |
* Healthcare Sector Average
IART
Integra Lifesciences
9.20
-12.49
-57.58%
CNMD
Conmed
34.58
-23.83
-40.80%
OFIX
Orthofix Medical
11.50
-4.56
-28.39%
UFPT
Ufp Technologies
189.45
-9.87
-4.95%
AXGN
AxoGen
31.28
12.92
70.37%
BVS
Bioventus
8.94
-0.09
-1.00%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.